Symbiosis’ Production Site Passes MHRA Inspection.
Symbiosis’ production site in Stirling, United Kingdom has recently passed an inspection from the Medicines and Healthcare Regulatory Agency (MHRA). The inspection ended with no critical or major observations noted.
Symbiosis was able to extend its MHRA regulatory licenses for the GMP sterile manufacturing of investigational medicinal products (IMPs) and aseptically filled licensed niche commercial products for clinical trials.
The company has also recently invested $1.9 million for the expansion of its production site by another 8,000-square-feet as demand in the cell and gene therapy market grows.
ILIAS Biologics has successfully raised $20.6 million in Series B funding.
Ilias biologics recently announced that they have managed to raise$20.6 million of funds in its Series B funding round.
Investors that participated are HB Investment, Timefolio Asset Management, Daedeok Venture Partners, Asset One, Devsisters Ventures, Meritz Securities, Kiwoom Securities, Daishin Securities, Hanyang Securities/Yeolim Partners, and Genie Asset Management and some private investors.
The current funding raised is at $40.2 million which will help Ilias Biologics to work on its exosome-based therapeutics pipeline.
CStone Pfizer and CStone entered into a strategic agreement to address the oncological needs in China.
CStone and Pfizer recently announced that they will enter a strategic collaboration involving a $200 million equity investment from Pfizer to develop and commercialize CStone’s sugemalimab (CS1001, PD-L1 antibody) in China.
Pfizer will exclusively have the license to commercialize the antibody in the Greater China market which will also enable the expansion of oncology assets distributed in the market.
This collaboration provides financing to support CStone’s development of sugemalimab, a potential best-in-class PD-L1 antibody that is being developed for high-incidence cancer indications in China, including lung, gastric, esophageal cancers, and more.